Petraglia F, Vannuccini S, Santulli P, Marcellin L, Chapron C
The exemplary biological preparation that is used for method of the present invention includes but not limited to gefitinib (Iressa), Anastrozole, diethylstilbestrol, estradiol, premarin, raloxifene, Progesterone, Norethynodrel, ethisterone (esthisterone), dimesthisterone, megestrol acetate, medroxyprogesterone acetate, hydroxyprogesterone caproate, norethindrone, methyltestosterone, testosterone, dexamethasone (dexamthasone), prednisone, hydrocortisone (Cortisol), prednisolone (solumedrol), tamoxifen, fulvestrant, toremifene, aminoglutethimide, testolactone, droloxifene), Anastrozole, bicalutamide, flutamide, nilutamide, goserelin, flutamide, leuprorelin, triptorelin, aminoglutethimide, mitotane, goserelin, Cetuximab, Erlotinib (erlotinib), imatinib, tositumomab, A Lun pearl monoclonal antibody (Alemtuzumab), Herceptin, lucky trastuzumab, Rituximab, ibritumomab tiuxetan, shellfish cut down pearl monoclonal antibody, denileukin diftitox (Denileukin diftitox), daclizumab, interferon-ALPHA, interferon beta, anti-4-1BB, anti-4-lBBL, anti-CD40, anti-CD 154, anti-OX40, anti-OX 40 l, anti-CD28, anti-CD80, anti-CD86, anti-CD70, anti-CD27, anti-HVEM, anti-LIGHT, anti-GITR, anti-GITRL, anti-CTLA-4, solubility OX40L, solubility 4-IBBL, solubility CD154, soluble g ITRL, solubility LIGHT, solubility CD70, solubility CD80, solubility CD86, soluble CTL A 4-Ig, with its combination
& Sadda, S
An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming
